Pure Global
NCT06400121

Apimostinel + Automated Neurocognitive Training for Depression

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single Intravenous Dose, Parallel Efficacy Study of Apimostinel With or Without Subsequent Automated Self-Association Training in Subjects With Major Depressive Disorder
Rebecca Price·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Depression
Drug/Device/Intervention
Apimostinel Infusion, Intravenous
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Rebecca Price
Funder
University of Pittsburgh
Location
Pittsburgh, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2024
End date
Dec 01, 2028
Enrollment
150 participants
Primary outcome

Montgomery-Asberg Depression Rating Scale (MADRS),Montgomery-Asberg Depression Rating Scale (MADRS)

Summary

Apimostinel shows initial promise as a novel rapid-acting antidepressant medication with
 minimal side effects or safety concerns. Cognitive Training (CT) is a digital intervention
 that has shown promise in extending the durability of another similar drug (ketamine). This
 randomized controlled trial will test the efficacy and safety of apimostinel (vs. saline) for
 the acute treatment of depression, and will test the potential of CT to enhance and/or extend
 the durability of apimostinel's antidepressant effect.

ICD-10 classifications
Depressive episodeOther depressive episodesRecurrent depressive disorderRecurrent depressive disorder, unspecifiedPost-schizophrenic depression
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06400121
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06400121 through Pure Global AI's free database. This Phase 2 trial is sponsored by Rebecca Price and is currently Not yet recruiting. The study focuses on Depression. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.